MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for spinal cord injury, survives and exhibits durable and robust human remyelination in spinal cord-injured rats for at least nine months following a single injection.
